Hsbc Holdings PLC Has $19.57 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Hsbc Holdings PLC decreased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,593 shares of the medical research company's stock after selling 12,538 shares during the period. Hsbc Holdings PLC owned 0.09% of Natera worth $19,573,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. lifted its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after buying an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares during the period. Principal Securities Inc. grew its stake in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after acquiring an additional 332 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 13,685 shares of the business's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $165.87, for a total transaction of $2,269,930.95. Following the completion of the sale, the chief executive officer now directly owns 253,944 shares of the company's stock, valued at approximately $42,121,691.28. The trade was a 5.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 2,562 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the transaction, the chief financial officer now directly owns 75,557 shares in the company, valued at $10,457,844.37. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 198,743 shares of company stock worth $30,558,447. Corporate insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NTRA. BTIG Research reissued a "buy" rating on shares of Natera in a report on Friday, February 28th. Royal Bank of Canada began coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. Guggenheim boosted their price target on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Robert W. Baird raised their price objective on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Finally, Piper Sandler boosted their price objective on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $175.76.

Natera Stock Down 0.4 %

NASDAQ NTRA opened at $153.79 on Friday. The stock's 50 day simple moving average is $147.95 and its 200 day simple moving average is $153.52. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a one year low of $90.88 and a one year high of $183.00. The firm has a market cap of $20.79 billion, a PE ratio of -87.38 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.